P0C024 (NUDT7_HUMAN) Homo sapiens (Human)

Peroxisomal coenzyme A diphosphatase NUDT7 UniProtKBInterProSTRINGInteractive Modelling

238 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3)

Available Structures

38 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of Human Peroxisomal coenzyme A diphosphatase NUDT7homo-3-mer13-233
10×EDO;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H5D;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0D;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;H3D;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0P;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H31;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H3A;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H2J;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H4G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H1J;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H5G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H47;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H1G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H3G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;GZY;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H1Y;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H54;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H1P;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;H0A;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0S;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H2D;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
H4A;ACT;DMS;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H3V;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H2G;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H17;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H2Y;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;B0V;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H4D;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H3J;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H1A;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0J;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H4Y;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H04;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H0M;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H3Y;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H2M;
Assess
PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Str…monomer14-209
ACT;DMS;H5A;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5t3p.1.Ahomo-3-mer0.8913-233
100.00
Assess
6gll.1.Amonomer0.5539-198
17.01
Assess

2 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 25t3p.1.Ahomo-3-mer0.8113-180
100.00
Assess
Isoform 35t3p.1.Ahomo-3-mer0.8113-124
94.31
Assess